Author:
Raderer M,Hamilton G,Kurtaran A,Valencak J,Haberl I,Hoffmann O,Kornek G V,Vorbeck F,Hejna M H L,Virgolini I,Scheithauer W
Publisher
Springer Science and Business Media LLC
Reference26 articles.
1. American Cancer Society (1991). Cancer Facts and Figures 1991, American Cancer Society: Atlanta
2. Anthony, L., Johnson, D., Hande, K., Shaff, M., Winn, S., Krozely, M. & Oates, J. (1993). Somatostatin analogue phase I trials in neuroendocrine neoplasms. Acta Oncol 32: 217–223.
3. Bauer, W., Briner, U., Doepfner, W., Haller, R., Huguenin, R., Marbach, P., Petcher, T. H. & Pless, J. (1982). SMS 201-995: a very potent and selective octapeptide analogue of somatostatin with prolonged action. Life Sci 31: 1133–1140.
4. Buscail, L., Saint-Laurent, N., Chastre, E., Vaillant, J. C., Gespach, C., Capella, G., Kalthoff, H., Lluis, F., Vaysse, N. & Susini, C. (1996). Loss of sst2 somatostatin receptor gene expression in human pancreatic and colorectal cancer. Cancer Res 56: 1823–1827.
5. Canobbio, L., Boccardo, F., Cannata, D., Gallotti, P. & Epis, R. (1992). Treatment of advanced pancreatic carcinoma with the somatostatin analogue BIM 23014. Cancer 69: 648–650.
Cited by
13 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献